Immune Environment and Osteosarcoma
暂无分享,去创建一个
[1] M. Heymann,et al. Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.
[2] M. Heymann,et al. RANK–RANKL signalling in cancer , 2016, Bioscience reports.
[3] N. Matsumura,et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues , 2016, International Journal of Clinical Oncology.
[4] D. Heymann,et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. , 2016, American journal of cancer research.
[5] C. Gomes,et al. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. , 2016, Translational research : the journal of laboratory and clinical medicine.
[6] S. Aiba,et al. The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages. , 2015, The Journal of investigative dermatology.
[7] S. Roberts,et al. Immunotherapy of Childhood Sarcomas , 2015, Front. Oncol..
[8] D. Heymann,et al. Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment , 2015, International journal of cancer.
[9] L. Diller,et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.
[10] S. Aiba,et al. Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Promotes the Production of CCL17 from RANK|[plus]| M2 Macrophages , 2015 .
[11] E. Álava,et al. Bone microenvironment signals in osteosarcoma development , 2015, Cellular and Molecular Life Sciences.
[12] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[13] A. L. Bosch,et al. CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study , 2015, Oncoimmunology.
[14] A. Goldhirsch,et al. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. , 2015, Cancer treatment reviews.
[15] Yue Zhou,et al. Expression of programmed death 1 is correlated with progression of osteosarcoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[16] P. Ordóñez-Morán,et al. Complex metastatic niches: already a target for therapy? , 2014, Current opinion in cell biology.
[17] P. De Baetselier,et al. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression , 2014, Front. Immunol..
[18] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Z. Duan,et al. Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential , 2014, Oncoimmunology.
[20] M. De la Fuente,et al. Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.
[21] Yu Yang,et al. Inhibition of macrophage polarization prohibits growth of human osteosarcoma , 2014, Tumor Biology.
[22] Mark S. Anderson,et al. Brief Definitive Report , 2022 .
[23] M. Schilham,et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.
[24] R. Gorlick,et al. Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma , 2014, Cancer.
[25] Klaus Pantel,et al. Tumor metastasis: moving new biological insights into the clinic , 2013, Nature Medicine.
[26] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[27] T. Hagemann,et al. Tumour-associated macrophages and cancer. , 2013, Current opinion in pharmacology.
[28] D. Hughes,et al. Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression , 2013, Front. Oncol..
[29] S. Lessnick,et al. Children's Oncology Group's 2013 blueprint for research: Bone tumors , 2013, Pediatric blood & cancer.
[30] M. Heymann,et al. Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.
[31] T. He,et al. The Current and Future Therapies for Human Osteosarcoma. , 2013, Current cancer therapy reviews.
[32] Yuquan Wei,et al. Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.
[33] A. Evdokiou,et al. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. , 2012, Biochimica et biophysica acta.
[34] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[35] I. Ostrovnaya,et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. Mueller,et al. Emerging Functions of RANKL in Lymphoid Tissues , 2012, Front. Immun..
[37] Kathryn L. Parsley,et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma , 2012, Clinical and Translational Oncology.
[38] I. Holen,et al. Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.
[39] Anne-Marie Cleton-Jansen,et al. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.
[40] J. Cheng,et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.
[41] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] P. Picci,et al. Palliative therapy for osteosarcoma , 2011, Expert review of anticancer therapy.
[43] T. Dønnem,et al. Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas , 2011, PloS one.
[44] D. Heymann,et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.
[45] D. Heymann. Interleukin-34: An enigmatic cytokine , 2010 .
[46] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[47] E. Kleinerman,et al. Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group , 2010, Clinical Cancer Research.
[48] S. Gordon,et al. Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.
[49] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[50] S. Bielack,et al. The role of radiotherapy in oseosarcoma. , 2009, Cancer treatment and research.
[51] T. Suda,et al. Cancer stem cells and their niche , 2009, Cancer science.
[52] G. Basak,et al. Multiple myeloma bone marrow niche. , 2009, Current pharmaceutical biotechnology.
[53] B. Trinité,et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. , 2008, Cancer research.
[54] H. Takayanagi,et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. , 2008, Immunity.
[55] L. Williams,et al. Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.
[56] Paul A Meyers,et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[58] E. Horwitz,et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. , 2007, Blood.
[59] B. Le Goff,et al. Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.
[60] D. Heymann,et al. Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.
[61] J. Pollard,et al. Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.
[62] Piero Picci,et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. , 2005, European journal of cancer.
[63] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[64] S. Théoleyre,et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma , 2005, BMC Cancer.
[65] R. Rezzonico,et al. The receptor activator of nuclear factor (NF)κB ligand (RANKL) is a new chemotactic factor for human monocytes , 2003 .
[66] S. Gordon,et al. Monocyte heterogeneity and innate immunity. , 2003, Immunity.
[67] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[68] Noam Brown,et al. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.
[69] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[70] K. Hirokawa,et al. Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus. , 2001, Endocrinology.
[71] Kristi Kincaid,et al. M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.
[72] S. Larson,et al. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. , 1998, International journal of oncology.
[73] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[74] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[75] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[76] J. Månsson,et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.
[77] N. Cheung,et al. Disialoganglioside GD2 anti‐idiotypic monoclonal antibodies , 1993, International journal of cancer.
[78] E. Kleinerman,et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] P. Hersey,et al. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma , 1988, International journal of cancer.
[80] N. Cheung,et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. , 1987, Cancer research.
[81] N. Berger,et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] G. Rosen,et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma , 1975, Cancer.
[83] R. van Furth,et al. THE ORIGIN AND KINETICS OF MONONUCLEAR PHAGOCYTES , 1968, The Journal of experimental medicine.
[84] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[85] S. Gottschalk,et al. Genetically modified T-cell therapy for osteosarcoma. , 2014, Advances in experimental medicine and biology.
[86] Dean Anthony Lee,et al. Natural killer cells for osteosarcoma. , 2014, Advances in experimental medicine and biology.
[87] Zhaoxu Li. Potential of human γδ T cells for immunotherapy of osteosarcoma , 2012, Molecular Biology Reports.
[88] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[89] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[90] K. Hirokawa,et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. , 2001, Endocrinology.
[91] K. Trieb,et al. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. , 1998, Pathology, research and practice.